Latest Conference Articles

Aleksandra Rachitskaya, MD, FASRS, is a member of the Modern Retina editorial advisory board.

The International Retinal Imaging Society (IntRIS) had a significant presence at this year's EURETINA Congress.

In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration.

This year's EURETINA meeting boasts a crowd of 10,000 attendees, including delegates, industry leaders, and young retina specialists.

Prithvi Ramtohul, MD, is a PhD candidate based in Marseille, France and previously completed a fellowship in Paris under Prof. Tadayoni.

BVI launches Virtuoso, a groundbreaking dual-function surgical platform for cataract and vitreoretinal procedures, enhancing efficiency and control in surgery.

Where to find members of our editorial board at this year's European Society of Retina Specialists Congress.

Leading companies to unveil new research on retinal diseases at EURETINA 2025, showcasing innovative therapies and clinical trial results.

Advancements in retinal therapies and technologies are scheduled to be showcased at EURETINA 2025 from Clearside, ZEISS, and Ashvattha Therapeutics.

At the 2025 EURETINA Congress, keep an eye out for 11 editorial advisory board members from Modern Retina, Ophthalmology Times and Ophthalmology Times Europe.

Retina specialists will celebrate the major anniversary this September in Paris, France.

Research reveals a significant link between androgen exposure and central serous chorioretinopathy, aiding clinicians in assessing patient risk factors effectively.

Research reveals that GLP-1 medications, including semaglutide, do not increase diabetic retinopathy risks, offering reassurance for patients and prescribers.

Research reveals how neighborhood social factors impact patients with tractional retinal detachments, highlighting the need for improved access to care and support.

A look at podium presentations on GA research at ASRS 2025.

Franklin shares how methotrexate significantly reduces reoperation rates in diabetic patients with retinal detachments, enhancing postoperative outcomes and vision.

The DAVIO-2 study reveals EYP-1901's potential as a 6-month treatment for neovascular AMD, matching aflibercept's vision outcomes with fewer doses.